Chronic Pain and Non-Med Janetta L Iwanicki, MD¹, Andrea C Besharat

² Clinical

Backgro

- Data on non-medical use (NMU) of prescriptio limited.
- Given the high prevalence of chronic pain, it is individuals.

Objecti

 Compare prescription opioid use and NMU in reported to an online United Kingdom (UK) nat

Metho

- The online survey was launched in July 2014 Lifetime reports of chronic pain ("pain lasting a flaring up frequently") and prevalence of lifetim (without doctor's prescription or for any reason were analysed.
- Odds ratios (ORs) were calculated by active p


Resu

- Of 2,499 respondents, 1,132 (45.3%) reported Opioid use was more common in those with cl (890 [35.6%]) (Table 1).
- Among respondents reporting opioid use:
 - Those with chronic pain were older (52.0 year Chronic pain was more common in females (
- Opioid use was two to four times more likely in API=1.8-3.9, p<0.05) (Figure 1).
- Of opioid users, NMU was reported by 507 (26) without (p=0.2517) (Table 3).

Conclus

- Opioid use is common in respondents.
- NMU appears common though unrelated to ch respondents both with and without chronic pai Feasibility of evaluating this topic via an online groundwork for future studies in Canada.

Figure 1. Ratio of Use Among to Those V




The RADARS System is supported by subscriptions from pharmaceu services. RADARS System is the property of Denver Health and Hos Colorado. Denver Health retains exclusive ownership of all data, data collection or analysis, nor do they have access to the raw data.

dical Use of Prescription t, MPH ¹ , Erin M Goodman, MS ¹ , Paul I Da ¹ Rocky Mountain Poison & Drug Cer Toxicology, Guy's and St. Thomas' NHS Fou	rgan, N Inter, Der
bund	
on opioids in patients with chronic pain are	
s important to understand NMU in these	
ves	Opioi
those with and without chronic pain as a tional survey.	
ds	
via a survey administration company. at least 3 months occurring constantly or ne prescription opioid use and NMU n other than recommended by doctor)	
harmaceutical ingredient (API).	
ts d chronic pain. hronic pain (1,031 [41.3%]) than without	Gende
rs ± 14.8 versus 46.2 ± 15.8) (Table 2). 52.2%) than males (47.8%) (Table 2). n those with chronic pain (ORs by	Age
6.4%) with chronic pain and 461 (24.0%)	
ions	
nronic pain; approximately one-quarter of in reported NMU. a survey is demonstrated, providing	Opioi
Those With Chronic Pain Vithout	Fig
<pre></pre>	Drug category
itical manufacturers for surveillance, research and reporting pital Authority, a political subdivision of the State of abases and systems. Subscribers do not participate in data	Guy's a

ioids in a United Kingdom National Survey ID², David M Wood MD², Richard C Dart, MD, PhD¹, Jody L Green, PhD¹

nver Health, Denver, CO, USA Trust and King's Health Partners, London, UK



Chronic Pain		
: Pain		
No	p-value	
n=1,367	Praide	
890 (35.6) <0.0001		
477 (19.1)	<0.0001	
phics Among Those		
d <u>Use</u>		
Chronic Pain		
	No	
	n=890	
483 (54.3)		
407 (45.7)		
	16.2 ± 15.8	
se and Chro c Pain	onic Pain	
No		
n=890	p-value	
461 (24.0)	0.2517	
429 (22.3)		
se Among Those With		
se Without		
2.50 3.00	3.50 4.00	
ADARS®	DENVER	
SYSTEM HEALTH		
	Level One Care for ALL	